Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
21 sept. 2023 08h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Second Quarter 2023 Financial Results
22 août 2023 09h29 HE
|
Purple Biotech Ltd.
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
11 juil. 2023 08h15 HE
|
Purple Biotech Ltd.
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
16 mai 2023 16h00 HE
|
Purple Biotech Ltd.
Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
Purple Biotech Debuts Scientific Advisory Board
25 avr. 2023 08h00 HE
|
Purple Biotech Ltd.
Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE...
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
19 avr. 2023 08h15 HE
|
Purple Biotech Ltd.
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
18 avr. 2023 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
24 mars 2023 07h00 HE
|
Purple Biotech Ltd.
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 ...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
16 mars 2023 07h00 HE
|
Purple Biotech Ltd.
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- ...
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
14 févr. 2023 07h01 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...